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Due to impressive improvements in surgical repair options, even patients with complex congenital heart disease (CHD)may survive
into adulthood and have a high risk of end-stage heart failure.Thus, the number of patients with CHDneeding heart transplantation
(HTx) has been increasing in the last decades. This paper summarizes the changing etiology of causes of death in heart failure in
CHD.Themain reasons, contraindications, and risks of heart transplantation in CHD are discussed and underlined with three case
vignettes. Compared to HTx in acquired heart disease, HTx in CHD has an increased risk of perioperative death and rejection.
However, outcome of HTx for complex CHD has improved over the past 20 years. Additionally, mechanical support options
might decrease the waiting list mortality in the future. The number of patients needing heart-lung transplantation (especially for
Eisenmenger’s syndrome) has decreased in the last years. Lung transplantation with intracardiac repair of a cardiac defect is another
possibility especially for patients with interatrial shunts. Overall, HTx will remain an important treatment option for CHD in the
near future.
1. Introduction
Since the first successful heart transplantation in a human by
Christiaan Barnard in 1967 [1], heart transplantation (HTx)
has evolved from its experimental stage to an established
treatment option for patients in end-stage heart failure [1–
3]. In 1967, the allograft survived six hours. Only with the
introduction of cyclosporine, further pediatric transplants
followed in the 1980’s.While historicallymost patients under-
going orthotopic HTx suffered from end-stage ischemic
or dilated cardiomyopathy, the proportion of patients with
congenital heart disease has increased [4].
Congenital heart disease (CHD) is common affecting
0.4–1% of the population. With the advent of modern heart
surgery, the majority of these patients, even those with com-
plex lesions, now survive to adulthood [5, 6]. Thus, there is
an increasing number of adult survivors with complex CHD
[5]. Despite these incredible improvements in surgical repair
options and thus outcome, many survivors of infant heart
surgery for CHD are not cured and some remain at high
risk of developing end-stage heart failure as young adults.
Heart failure contributes importantly to the late morbidity
and mortality in adult CHD [7–9]. In the end-stage of their
disease, orthotopic HTx currently often remains the only
viable treatment option.Given these changes in epidemiology
of patients with CHD, over the next few decades we expect a
rapidly increasing population of adults with CHD that will be
assessed for HTx [10].
In the paper we will discuss specific issues and challenges
in the pre, peri, and post-transplantation period of these
patients and illustrate some of these pertinent issues with
real-life patient vignettes.
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Table 1: Main reasons for heart transplantation in congenital heart
disease.
(i) Primary heart transplantation (newborn HTx for HLHS or
Ebstein’s anomaly)
(ii) Eisenmenger syndrome with simple CHD with left to right
shunting (acyanotic)
(iii) Tetralogy of Fallot (repaired or palliated), and other complex
CHD (cyanotic)
(iv) Univentricular heart with and without Fontan circulation
(v) Systemic right ventricle (CCTGA or TGA after atrial switch
operation)
HTx: heart transplantation; HLHS: hypoplastic left heart syndrome; CHD:
congenital heart disease; CCTGA: congenitally corrected transposition of the
great arteries; TGA: transposition of the great arteries.
2. Changing Mortality Patterns and
Causes of Death in CHD
To understand current and to predict future patient cohorts
at risk for end-stage CHD, it is important to review the
changes and evolution of surgical treatment strategies for
complex CHD over the last few decades. This evolution
will have a major impact on the total number of individuals
with certain complex congenital heart lesions and the age
distribution within these cohorts. It is also important to
analyze causes and modes of deaths and their changes.
Recent studies have demonstrated that childhood mor-
tality in CHD has almost disappeared and mortality has
shifted almost entirely to adulthood [11].Themain reasons for
HTx are shown in Table 1. While primary transplantation for
newborns and infants with hypoplastic left heart syndrome
or the severest forms of Ebstein’s anomaly of the tricuspid
valve may be valuable treatment options in selected cases,
surgical palliation along the Norwood route is nowadays
attempted at most centers.The underlying congenital cardiac
defects in 164 adults with CHD who died from their disease
during followup in a single center reported by Oechslin et
al. were shunt lesions with Eisenmenger physiology (29%),
patients with repaired tetralogy of Fallot (10%), patients with
univentricular hearts (8%), and patients with systemic right
ventricles (6%) [7]. In a national registry for ACHD patients
in the Netherlands including 6,933 patients, 197 patients died
at a median age of 49 years: the most common diagnoses
were atrial septal defects (17%), tetralogy of Fallot (12%),
aortic stenosis/bicuspid aortic valves (9%), systemic right
ventricles (9%), and univentricular hearts (6%) [12]. Within
these series, end-stage heart failure contributed substantially
to late mortality and contributed to roughly one third of all
late deaths [7–9].The specific etiology of heart failure inCHD
is summarized in Table 2.
3. Congenital Cardiac Defects at
Risk for End-Stage Heart Failure
While there has been a slow decline in the number of adult
heart transplants for acquired heart disease over the last
few decades, the proportion of HTx for end-stage ACHD
Table 2: Etiology of heart failure in congenital heart disease.
Primary heart dysfunction
Valvular regurgitation or stenosis
Congenital shunt lesions or systemic pulmonary shunts
Long-standing cyanosis
Arrhythmias
Dysfunction of the subpulmonic ventricle
Inherited abnormalities of the myocardium
Oxygen supply-demand mismatch
The Fontan circulation per se
Associated congenital heart disease in visceral heterotaxy
has slightly decreased [14]. The proportion of CHD among
transplant recipients is also very much dependent on the
age at transplantation. According to the 2010 report of the
International Society for Heart and Lung Transplantation
Registry CHD was present in 63% of patients undergoing
HTx < 1 year of age, 37% of those 1–10 years of age, 25% in
patients 11–17 years of age, and only 2% of adult recipients.
[15]. Given the expected changes of the epidemiology of
CHD, these trends are expected to further change in the near
future with a shift of transplants from the pediatric to the
adult area of congenital heart disease. Thus, the face of heart
transplantation is slowly changing [2, 4].
In single center studies, the most frequent individual
congenital cardiac diagnoses in patients undergoing HTx are
single ventricle physiology with or without Fontan pallia-
tion, transposition complexes with systemic right ventricles
(complete transposition after atrial switch procedures or
congenitally corrected transposition of the great arteries), and
patients with repaired or palliated tetralogy of Fallot [16].
4. Etiology of Heart Failure in ACHD
Although neurohumoral activation in CHDpatients with cir-
culatory failure is very similar to patients with acquired heart
disease, causes of circulatory failure in CHD aremore diverse
[17]. Etiology of heart failure (see Table 2) includes primary
systolic or diastolic ventricular dysfunction and/or progres-
sive valvular regurgitation or stenosis. Factors predisposing
to ventricularmyocardial dysfunction are long-standing ven-
tricular volume or pressure overload due to valvular regurgi-
tation, congenital shunt lesions, or surgically created systemic
to pulmonary shunts. Additional contributing factors are
long-standing cyanosis, prior surgical ventricular incision,
and uncontrolled arrhythmias. Adverse ventriculoventricular
interactions are increasingly recognized as an important
contributor to systemic ventricular dysfunction in patients
with dilatation and dysfunction of the subpulmonic ventricle
[18]. Additionally, theremay be inherited abnormalities of the
myocardial structure in patients with CHD such as noncom-
paction which is more common in Ebstein’s anomaly [19] and
other patients with CHD [20]. In patients with a systemic
right ventricle such as patients with congenitally corrected
transposition of the great arteries (CCTGA) and patients
Journal of Transplantation 3
with complete transposition of the great arteries (D-TGA)
repaired with an atrial switch operation (Mustard or Senning
procedure), an oxygen supply-demand mismatch may lead
to myocardial ischemia and fibrosis. In these patients sub-
stantial atrioventricular valve regurgitation is often present
and associated with an increased preload and is felt to be
an ominous sign of impending ventricular failure [21–23].
Both systolic dysfunction of the systemic RV and progressive
tricuspid regurgitation have been associated with increased
mortality.
In CCTGA retrospective multi-institutional studies
clearly demonstrate an increasing incidence of systemic and
ventricular dysfunction and clinical congestive heart failure
with advancing age [24, 25]. Even in patients with CCTGA
and no significant associated lesions, more than one third
had congestive heart failure by the fifth decade of life [24, 25].
As clinical worsening is often caused by progressive systemic
AV valve regurgitation, timely systemic atrioventricular
valve replacement may offer the best prevention of further
deterioration and may postpone or even prevent the need for
HTx.
The Fontan circulation for palliation of patients with uni-
ventricular physiology represents a unique form of modified
CHD. Most adult survivors with this type of physiology still
have modified atriopulmonary types of Fontan procedures.
In the future, novel cohorts of patients with lateral tunnel
Fontan’s or total extracardiac cavopulmonary anastomosis
will emerge.The rate of complications among Fontan patients
increases in the third and fourth decade of life. Given the
evolution of these procedures over the last 4 decades these
cohorts are still, emerging and in the future we expect many
more patients with “failing Fontans.” The malfunction of the
Fontan circulation has many contributors, with single ven-
tricular dysfunction being just one component. In addition,
in this patient group atrial arrhythmias are very common,
and chronically elevated systemic venous pressures often lead
to hepatic fibrosis or cirrhosis. Protein losing enteropathy is
a dreaded long-term complication and associated with poor
long-term survival. While surgical conversion of an atri-
opulmonary Fontan to a total cavo-pulmonary anastomosis
may be a good treatment option for selected patients, many
with advanced circulatory failure and multiorgan affection
may have a very high perioperative mortality, and thus
transplantation may be a more favorable treatment option in
these individuals (see patient vignette 1).
5. Case Vignette 1: A 31-Year-Old
Patient with Failing Fontan
The patient was born with tricuspid atresia, atrial and ven-
tricular septal defects, and severe infundibulary pulmonary
stenosis. He underwent surgical palliation with a Fontan
procedure, initially using an atrial to right ventricular con-
duit, later converted to an atriopulmonary Fontan-Kreutzer-
Anastomosis due to conduit failure. Until the age of 11 years
he already had had a total of 5 sternotomies. At the age of
17 years he needed implantation of an epicardial pacemaker
for sinus node dysfunction. In his late 20s he experienced
progressive decline of exercise capacity developed refractory
atrial arrhythmias and finally progressive Fontan-failure with
cardiac cachexia, intractable ascites, liver cirrhosis, mild
protein losing enteropathy, and severe renal dysfunction
(see Figure 1). He had recurrent hospital admissions for
heart failure and worsening renal function. At the age of 31
years, he was listed for HTx and received an organ after 9
months on the waiting list. At the time of transplantation
extensive reconstruction of the pulmonary arteries had to
be performed. He had a surprisingly smooth postopera-
tive course with immediate recovery of renal function and
was discharged 4 weeks after transplantation. Macroscopic
and histologic images of the explanted heart are shown in
Figure 2.
As survivors of Norwood palliation are only just reaching
adulthood, we are not dealing with this entity in this paper.
Cardiac transplantation in children with visceral heterotaxy
as described by Larsen et al. can be an option with a 10-year
mortality of 50% [26]. In case vignette 2, we describe one of
our patients with visceral heterotaxy which is not considered
for HTx yet.
6. Case Vignette 2: Complex Cardiac Anatomy
A 24-year-old patient was assessed for cardiac transplanta-
tion. She was born with left atrial isomerism with venous
drainage of the lower body half via hemiazygos continuation
to a single left superior caval vein. Liver veins drain directly
to a single atrium. Intracardiac defects comprised a single
atrioventricular valve with a severely hypoplastic ventricle
and severe subvalvar pulmonary stenosis (see Figure 3). She
underwent palliation with right modified Blalock-Taussig-
Shunt. At the age of 18 years she underwent emergent
recanalization and stenting due to thrombotic occlusion of
the Blalock-Tausig-Shunt. At that time slightly elevated pul-
monary artery pressures were recorded, precluding a Fontan-
procedure. In her early twenties the patient developed severe
atrioventricular valve regurgitation with progressive exercise
intolerance. Atrioventricular valve repair was discussed but
was declined due to the expected very high perioperative
mortality. Transplantation was deemed technically possible,
though challenging given the complex venous anatomy and
borderline elevated pulmonary pressures. Prior to listing, she
is currently kept under close clinical surveillance with serial
imaging and cardiopulmonary exercise testing with the aim
to list the patient for transplantation in the event of further
deterioration of exercise capacity.
7. Specific Considerations for
Heart Transplantations in
Congenital Heart Disease
In patients with ACHD and end-stage circulatory failure, the
following three issues add to the complexity of transplanta-
tion: (1) tools for prognostication in ACHD patients are not
well established and may differ between different congenital
cardiac disease entities. Whether or not it is legitimate to
adopt prognostic scores from patients with acquired heart
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Figure 1: 31-year old patient with tricuspid atresia, atrial and ventricular septal defects, and severe infundibular pulmonary stenosis.
He underwent surgical palliation with a Fontan procedure, initially using an atrial to right ventricular conduit, later converted to an
atriopulmonary Fontan-Kreutzer-Anastomosis due to conduit failure. After increasing heart failure and 5 cardiac surgeries, he underwent
heart transplantation. (a) Chest X-ray with massive cardiac enlargement and the epicardial pacemaker. (b) Subcostal echocardiographic
view showing severely dilated right atrium (RA) with spontaneous echocontrast and perihepatic ascites (bold arrow). (c) Axial plane of
chest-computed tomogram showing giant right atrium (RA) and normal-sized left ventricle (LV). (d) Coronal plane of chest and abdominal
computed tomography showing enlarged right atrium (RA) with connection to themain pulmonary artery (arrow) and hepatomegaly (arrow
head).
disease remains to be seen. As complicating factors, some
of the patients with CHD have anomalies of the systemic or
pulmonary venous return or situs inversus or dextrocardia.
They may additionally need concomitant aortic arch correc-
tion in patients with hypoplastic left heart syndrome needing
HTx. Also assessment of pulmonary vascular resistance after
previous Glenn and Fontan circulation may be difficult. (2)
Most adults with CHD had previous open heart surgery
necessitating often multiple interventions, which adds to
the complexity of the surgical procedure at the time of
transplant. Additionally, aortopulmonary collaterals increase
the bleeding risk. In the presence of increased pulmonary
venous return, the operating field may be hard to visualize
sufficiently. In some patients, perfusion with the heart-lung
machine may be almost impossible necessitating circulatory
arrest in deep hypothermia. (3) Because of the previous use
of blood transfusions or repair with homograft tissue, the rate
of preformed HLA antibodies is increased.
To address these difficulties, a close collaboration among
ACHD specialists, heart failure specialists, transplant sur-
geons and anesthesiologists is needed for optimal care of
these patients.
8. Prognostication of Survival
Timely identification of possible candidates for HTx is es-
sential for patients without but also with CHD. In patients
with acquired heart disease, maximal oxygen consumption
per unit time (𝑉O
2
) has been used as an important criterion
for listing for transplantation. Traditionally 𝑉O
2
maximum
of <12–14mL/kg/min in patients without beta-blocker treat-
ment and <10mL/kg/min in those on beta blocker therapy
have been used as one of the criteria for listing for transplan-
tation. Although it has been shown in a study with ACHD
patients that decreased 𝑉O
2
is associated with an increased
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Figure 2: Explanted heart of a 31-year-old patient with failing Fontan. (a) Macroscopic view of the explanted heart, showing the tricuspid
atresia (TA)with hypoplastic right ventricle (RV), grossly dilated right atrium (RA) and left ventricle with septal hypertrophy. (b) and (c) show
histologic cuts of the right ventricular myocardium with areas of interstitial myocardial fibrosis (arrow) and areas of marked endomyocardial
fibroelastosis (arrow head).
risk of hospital admission or death [27], it is not known
whether the same 𝑉O
2
-thresholds should be used for listing
for transplantation and whether thresholds are independent
of the underlying congenital cardiac defect. In a large study
1,375 consecutive adult patients with CHD (age, 33±13 years)
were included who underwent cardiopulmonary exercise
testing at a single center over a period of 10 years with a
median followup of 5.8 years. In this group, 117 patients
died with the risk of death increased with lower peak 𝑉O
2
and lower heart rate reserve [28]. Of note, self-reported
exercise tolerance poorly correlated with objective measures
of exercise capacity and thus serial standardized exercise
testing is strongly recommended in long-term followup [29].
So far, BNP levels have been shown to be predictors of
sudden cardiac arrest (SCA) and ventricular arrhythmias
in patients without CHD [30]. BNP levels also correlate
with diminished function of the systemic right ventricle
and parallel the degree of tricuspid regurgitation and thus
outcome [31]. Recently, in a study involving 181 patients with
Eisenmenger syndrome (31% with Down syndrome) during
a median followup period of 3.3 years, 20 patients (7 with
Down syndrome) died [32]. Higher BNP concentrationswere
predictive of all-cause mortality on univariate analysis in
patients with or without Down syndrome. On multivariable
Cox-proportional hazard analysis, BNP predicted survival
independently of renal function, Down syndrome, or 6min
walk test distance (𝑃 = 0.004). Temporal increases in BNP
concentration were also found to predict mortality [32].
As for acquired heart disease anemia, hyponatremia, and
renal dysfunction [33–35] have been identified as markers
for mortality risk in ACHD patients. Further additional risk
factors such as pulmonary hypertension, recurrent hospital
admissions for heart failure or cardiac cachexia may be
important factors for adverse outcome. Evenmore important
as the result of single testingmay be changes during followup.
For optimal long-term assessment of patients with ACHD
we thus recommend to use standardized serial followup
examinations following strict institutional protocols. In the
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Figure 3: 24 year old patient with heart failure and complex cardiac anatomy in the setting of left atrial isomerism. (a): Chest X-ray. (b):
Axial slice of cardiac magnetic resonance imaging, showing a single atrium (SA) with direct connection of hepatic veins (arrow), dominant
right ventricle (RV) and hypoplastic left ventricle (LV). (c): Coronal slice of cardiac magnetic resonance imaging showing hemiazygous
continuation to left superior caval vein (arrows) in the absence of a right superior caval vein. (d): Apical echocardiographic viewdemonstrating
the dominant right ventricle (RV), the hypoplastic left ventricle (LV), the enlarged single atrium (SA) and the dysplastic tricuspid valve. On
the right hand of the panel color Doppler demonstrates severe tricuspid regurgitation.
absence of systematic prospective validation of risk factors
decision making about timing of transplantation in ACHD
patients has to be individualized. For this purpose all available
individual risk factors and modifiers have to be taken into
account and weighed against the expected individual peri-
operative morbidity and mortality of a transplant procedure.
The risk factors for HTx are summarized in Table 4.
Many adults with congenital heart diesease are at inreased
risk of SCA. In individual patients risk stratification is how-
ever difficult and depends on the type of underlying defects
and additional factors. Prospective studies demonstrating a
benefit for primary prophylaxis of AICD-implantation are
unfortunately lacking, and risk stratification depends on
retrospective analysis of single or multi center cohorts. In a
recent single center study, 936 adults with previously repaired
CHD and amean age at first examination of 21±7 years were
followed during 9 ± 7 years. During followup, SCA occurred
in 22 patients (2.6 per 1,000 person-years) with highest
incidence in patients with transposition complexes [36].
Age at initial examination and severely impaired subaortic
ventricular systolic function were independent risk factors
for SCA (severe subaortic ventricular systolic dysfunction,
adjusted hazard ratio 29, 95% confidence interval 11 to 72,𝑃 <
0.001). SCA occurred in 23% of patients with severe subaortic
ventricular systolic dysfunction versus 0.7% of patients with
nonsevere decreased subaortic ventricular function (𝑃 <
0.001). In contrast, a multicenter study of patients with AICD
implantation for the transposition of the great arteries after
atrial switch procedures did not show a benefit in those
implanted for primary prevention and a high rate of lead
complications and inappropriate shocks [37].Thus, currently,
the decisions for implantation of AICDs in patients on the
waiting list for HTx must be individualized. Multicenter
registries would be helpful to define benefit in the future.
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Figure 4: 32-year-old patient with severe biventricular dysfunction after atrial switch operation for complete transposition of the great arteries
with pacemaker leads in the subpulmonic left ventricle and the systemic venous baffle. (a) Chest X-ray with transvenous pacemaker leads. (b)
Apical “5-chamber”-view showing the aorta arising from the morphologic right and the pulmonary artery from the subaortic left ventricle
(RV: right ventricle, LV: left ventricle, AO: aorta, PA: main pulmonary artery, LPA: left pulmonary artery). (c) Apical 4-chamber view showing
the pulmonary venous and the systemic venous baffles, redirecting venous blood.The arrow points to the pacemaker lead in the subpulmonic
left ventricle. (d) Apical 4-chamber view with colour Doppler demonstrating severe (subpulmonic) mitral and severe (systemic) tricuspid
regurgitation.
9. Case Vignette 3: A Patient with Failing
Senning and Sudden Cardiac Death While
Awaiting Transplantation
A 32-year-old woman, born with complete transposition of
the great arteries and ventricular septal defect, was referred
for transplant assessment. She had an atrial switch operation
(Senning technique) at the age of 7 months. Surgical repair
was complicated by complete heart block with the need for
implantation of a pacemaker. At age 32, she developed biven-
tricular heart failure with severe pulmonary hypertension.
Exercise capacity was severely decreased (peak oxygen con-
sumption 8mL/kg/min). Echocardiography showed biven-
tricular dilatation, severe biventricular systolic dysfunction,
and severe regurgitation of both atrioventricular valves (see
Figure 4). Cardiac catheterization demonstrated borderline
pulmonary vascular resistance (3.3WU). The patient was
listed for cardiac transplantation. Subsequently she had sev-
eral admissions for decompensated heart failure. She died 3.5
months after listening due to sudden death at home. Prior to
sudden cardiac death she had never experienced syncope and
was never documented to have ventricular arrhythmias.
10. Contraindications for Heart
Transplantation in ACHD
Absolute and relative contraindications according to the
ACC/AHA guidelines for the management of ACHD are
summarized in Table 3.
In ACHD patients with renal dysfunction in the pre-
transplant period related to cardiac dysfunction but without
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Table 3: Contraindications for heart transplantation in adult con-
genital heart disease.
Absolute contraindications
Active infections (active hepatitis C and viral replication)
Severe metabolic disease
Other multiple severe congenital anomalies
Multisystem organ failure
Active malignancy
Cognitive/behavioral disability that interferes with compliance
Relative contraindications with increased morbidity
Diabetes with end-organ dysfunction
Irreversible renal dysfunction
Symptomatic cerebrovascular or peripheral vascular disease
not amenable to revascularization
Obesity with a pretransplant BMI >30 kg/m2
Active tobacco smoking and substance abuse
Elevated PVR
HIV positivity
Asplenia in right atrial isomerism
Residual shunts (high-output heart failure post-transplant)
BMI: body mass index; PVR: pulmonary vascular resistance; HIV: human
immunodeficiency virus.
Table 4: Risk factors for heart transplantation according to Lamour
et al. 2009 [13].
Variable Relativerisk 𝑃 value
Early phase
Previous Fontan 8.6 0.003
Higher pretransplant mean RAP
(only if previous Fontan) 2.4 <0.0001
Longer ischemic time 1.6 0.002
Older recipient age 1.5 0.02
Interaction of donor age and
ischemic time 1.4 0.0007
Constant phase
Previous classic Glenn operation 3.1 0.01
CMV +donor, CMV −recipient 2.8 0.001
Higher systolic transpulmonary
gradient 2.0 0.01
Younger recipient age 1.8 0.0001
Univentricular heart, previous
cardiac surgery, >1 year old 6.48 <0.0001
RAP: right atrial pressure; CMV: cytomegalovirus.
obvious renal disease, renal function often improves after
transplantation (see case vignette 1). Most ACHD patients
considered candidates for HTx are still young, and thus,
atherosclerotic disease as a risk factor for adverse outcome
in this population is rare. In ACHD patients, particular
attention has to be paid on pulmonary vascular resistance
(PVR). A fixed PVR index of>5WU/m2 or a transpulmonary
gradient >15mmHg not responsive to vasodilator therapy are
deemed to be contraindications. Of note, in patients with
Fontan palliation determination of PVR can be difficult in the
presence of venovenous collaterals and intracardiac shunts.
Patients with ACHD and irreversible pulmonary hyper-
tension may be candidates for combined heart-transplanta-
tion or lung transplantation with surgical repair of the under-
lying congenital heart lesion at the time of transplantation
[38]. The latter approach is usually reserved for patients with
relatively simple defects such as simple shunt lesions.
In the evaluation of patients for transplantation standard-
ized checklist such as the one proposed by theTorontoACHD
Heart Transplant Evaluation team are helpful [10].
Complex cardiac anatomy (i.e., heterotaxy syndromes),
multiple previous sternotomies or extensive collateral vessels
may be relative contraindications for HTx. Early involvement
of transplant surgeons and congenital cardiac surgeons is of
paramount importance to address these difficulties and to
assess transplant eligibility of an individual patient. Once
such a patient is listed, availability of surgeons with the
required expertise at the time of transplantation has to be
ascertained. Patients with situs inversus are the most difficult
anatomy for HTx. In patients with prior Glenn or Fontan
surgery, the pulmonary artery has to be reconstructed with
excess donor tissue. The same is true for the aortic arch in
hypoplastic left heart syndrome.
11. Waiting List Mortality in ACHD
Patients with ACHD often are identified at a relatively early
stage and thus are usually listed at a low urgency status and
consequently spend more time on the waiting list [39]; there
is a conflict of search for the ideal donor and transplant
environment versus the increased waiting list mortality seen
in ACHD [40].
Important is the recognition that ACHD patients do
receive ICDs less often than patients with acquired heart
disease [40]. Although general predictors for the benefit of
primary prevention of AICDs in ACHD cohorts are lacking,
the recognition that sudden cardiac death contributes sub-
stantially to waiting list mortality in these patients suggests
that a more liberal use of AICDs in ACHD patients listed for
HTx may reduce waiting list mortality [41].
As mentioned by Burchill and Ross in their review [10],
clinicians must carefully balance risks of premature listing
against progressive heart failure and increased waiting list
mortality. This is one of the most difficult tasks we encounter
as cardiologists caring for patients with complex, end-stage
CHD.
Increasingly, mechanical circulatory support is used in
patients with CHD prior to HTx in up to one third of
children [42] without an impact on long-term mortality. In
adults, mechanical circulatory assistance does not improve
waiting list probably due to a combination of complex reop-
erative surgery and poor preoperative health [14]. Mechan-
ical circulatory support of the single ventricle circulation
is sometimes the only option for saving the patient’s life
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and poses mechanical and physiological challenges. When
late failure occurs, beside ECMO support, ventricular assist
device (VAD) implantation may be considered as a bridge to
transplantation. In vitro tests have evaluated different VADs
especially for this setting [43–45]. Even if clinical experiences
with long-term VAD support are still limited due to the
complexity of the patients, the successful use of the Berlin
Heart Excor up to 363 days has been published in case
reports or case series [46], both in a “univentricular” [47]
and a “biventricular” setting [48]. Small implantable devices
like the Heartware HVAD may offer new options for these
patients as reported by the Berlin group [49].
12. Outcome after Heart Transplantation
for Congenital Heart Disease
Compared to patients with acquired heart disease, those
with ACHD face an increased risk of perioperative death
at the time of HTx [2, 3]. Causes for increased periopera-
tive mortality are more complex surgical procedure, often
requiringmajor reconstructive surgery and a higher bleeding
risk due to previous sternotomies. Donor right ventricular
failure secondary to pulmonary hypertensionmay contribute
as well. The highest risk for perioperative death was doc-
umented in neonates requiring circulatory support with
ECMO prior to transplantation [15]. Patients with CHD
also have an increased risk of rejection due to younger age,
a more powerful immune system and increased levels of
preformed HLA antibodies from prior blood transfusions
andhomograft implants at the time of reparative cardiac surg-
eries. Particularly the need for reconstruction of pulmonary
arteries has been identified as a risk factor for increased
perioperative and long-term mortality in some series [16].
Single ventricles following palliation have the worst outcome
with 1, 5, and 10-year survival of 70%, 58%, and 50%
[50].
In Fontan patients <18 years of age when listed, Bernstein
et al. [51] reported the outcome of HTx. Survival was 77% at
1 year and 67% at 5 years, significantly lower compared with
91% 1-year and 81% 5-year HTx survival for noncongenital
diagnosis. Overall mortality for HTx after Fontan failure was
33%. This data suggests that the increased risk in Fontan
patients is predominantly in the early period after transplan-
tation. In the Fontan group, there was a high rate of early graft
failure (17%), infections (30%), and hemorrhage/operative
complications (9%) as a cause of death, compared with other
CHD and non CHD diagnosis [52]. In a single-institution
experience with 155 patients undergoing HTX for CHD, 43
had a previous Fontan procedure: in 39.5% they had protein-
losing enteropathy, 41.8% chronic heart failure, and 9.3%
acute post-Fontan failure [39]. Patients undergoing HTx due
to “failing” Fontan were more likely to require pulmonary
artery reconstruction, which was necessary in 85.4% (𝑃 <
0.0001) and had longer cardiopulmonary bypass times (𝑃 <
0.0001). The 90-day mortality rate was 35% versus 20% in
other CHD (𝑃 = 0.055). Average age in this patient group
was 14.5 years [1–12, 14–48]. Only 12 patients were at least 20
years old at the time of HTx, and only 3 patients older than
30 years. Of these 12 patients, 7 died during followup. 90-
day mortality did not differ between the age groups; however,
after 1999 90 day mortality was 14.3% in those <18 years and
50% in those at least 18 years old (𝑃 = 0.09). So in patients
>18 years old with failed Fontan the outcomes after HTx
are still not well defined. In selected patients conversion of
an atriopulmonary Fontan to an extracardiac total cavopul-
monary anastomosis with arrhythmia surgery may even be
the preferred treatment strategy to postpone the need for
transplantation.
Overall, outcome for HTx for complex CHD has im-
proved annually over the past 20 years [16]; the highest risk
was transplant prior to 1990 (𝑃 = 0.01), respectively prior
to 1996 (𝑃 = 0.001). Males also had a better outcome (𝑃 =
0.02) [16]. Neonates had a worse outcome (𝑃 = 0.005).
Still, compared to patients with dilated cardiomyopathy in
most studies mortality in patients with CHD after HTx was
slightly worse than after dilated cardiomyopathy. In our own
experience, long-term survival after heart transplantation
performed in 13 adolescents and adults with CHD (mean age
of 27.5 years) was 77% 20 years, not significantly different
from an age-matched control-group transplanted for dilated
cardiomyopathy [53]. In a recent report pediatric patients
with CHD were found to have a trend towards an increased
risk of cardiac allograft vasculopathy with a relative risk of
1.36 (𝑃 = 0.08) potentially due to increased preformed
antibodies [15].
13. Heart-Lung or Lung Transplantation
Combined heart and lung transplantation or lung transplan-
tation with intracardiac repair of the CHD is considered
for patients with irreversible pulmonary hypertension or
inadequate sized pulmonary arteries (complex forms of
pulmonary atresia). The first heart-lung transplantation was
performed in 1981 in a patient with pulmonary arterial
hypertension [54]. The highest number of procedures was
performed in 1989 with a total of 284 in adult and 61 in
pediatric patients [55]. More recently, the numbers have
been decreasing again. In adult patients, the main cause for
heart-lung transplantation is Eisenmenger’s syndrome [56]
followed by idiopathic pulmonary arterial hypertension and
cystic fibrosis.
Double-lung transplantation with intracardiac repair of
the cardiac defect is an option in those with irreversible
pulmonary hypertension and simple intracardiac defects,
such as atrial or ventricular septal defects, aortopulmonary
windows, or Eisenmenger syndrome due to a large patent
ductus arteriosus [38].
In a series of including patients with adult CHD (ven-
tricular and atrial septal defect, patent ductus arteriosus,
etc.), 46 underwent heart-lung transplantations and 5 had
double lung transplantations [57]. In this series, survival
was 80%, 69%, and 53% at 1 year, 5 years, and 10 years:
this was not different from survival in patients without
CHD. So, despite high operative mortality due to a higher
incidence of complications, long-term prognosis in adult
CHD undergoing lung transplantation is excellent.
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14. Conclusion
There is a growing cohort of young adults with complex
congenital heart disease,many at risk for premature death due
to heart failure. Heart transplantation (HTx) is and will be
an important treatment option for selected ACHD patients
with end-stage circulatory failure. It improves quality of life
and survival in selected patients. Obstacles for successful
transplantation are technical challenges due to complex
anatomy and previous operations. In the absence of validated
tools for prognostication, optimal timing for transplantation
listing remains a major challenge and requires close multi-
disciplinary collaboration between ACHD specialists, heart
failure specialists, surgeons and many others. Institutional
protocols for serial followup of potential candidates are
essential. Mechanical circulatory support as a bridge to HTx
is an important option to consider especially in children
waiting for HTx.
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